Provided by Tiger Fintech (Singapore) Pte. Ltd.

ABVC BioPharma, Inc.

0.6459
-0.0421-6.12%
Post-market: 0.6394-0.0065-1.01%19:14 EDT
Volume:117.51K
Turnover:75.90K
Market Cap:8.38M
PE:-0.78
High:0.6797
Open:0.6479
Low:0.6120
Close:0.6880
Loading ...

Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital

GlobeNewswire
·
25 Feb

Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker

Business Wire
·
19 Feb

Alzamend Neuro Announces Completion of a Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials at Massachusetts General Hospital

Business Wire
·
19 Feb

Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

GlobeNewswire
·
18 Feb

This Stock Is Already Up by 55% in 2025: Is It Too Late to Buy?

Motley Fool
·
16 Feb

Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results

ACCESS Newswire
·
13 Feb

Positive Market Response in Asia Fuels Potential Revenue Growth for ABVC and BioKey, Marching Into Global Dietary Supplements Market of USD 75.35 Billion

NewMediaWire
·
12 Feb

Press Release: Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights

Dow Jones
·
11 Feb

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
08 Feb

Yukiguni Maitake to Launch 'Mushroom Meat' in Japan

MT Newswires Live
·
06 Feb

Yukiguni Maitake Launches ‘Mushroom Meat’ to Tackle Protein Crisis

TIPRANKS
·
05 Feb

NeuroStar Unveils Two Significant Publications on TMS Therapy for Depression

GlobeNewswire
·
29 Jan

Neurocrine initiates Phase 3 registrational program for osavampator in MDD

TIPRANKS
·
28 Jan

Supernus Pharmaceuticals Says US FDA Approves Label Update for ADHD Treatment Qelbree

MT Newswires Live
·
27 Jan

Supernus Announces Label Update for Non-Stimulant ADHD Treatment, Qelbree®, Including New Pharmacodynamic Data and Information for Breastfeeding Women

GlobeNewswire
·
27 Jan

People with ADHD are more likely to die early, according to a new study

businessinsider.com
·
24 Jan